The text starts here.

News Release

10/12/2018
NEW DRUG APPLICATION FOR PERAMPANEL FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES ACCEPTED IN CHINA
09/05/2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) APPROVAL OF LENVIMA® (LENVATINIB) FOR TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARC
08/29/2018
LENVIMA® (LENVATINIB) CAPSULES APPROVED FOR FIRST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN SOUTH KOREA
08/28/2018
LONG-TERM CARDIOVASCULAR OUTCOMES DATA FOR ANTI-OBESITY AGENT BELVIQ® PRESENTED AT THE EUROPEAN SOCIETY OF CARDIOLOGY AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE
08/23/2018
EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR LENVIMA® (LENVATINIB) AS FIRST-LINE TREATMENT IN ADULTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA
08/17/2018
EISAI AND MERCK & CO., INC., KENILWORTH, N.J., U.S.A. ANNOUNCE FDA APPROVAL OF LENVIMA® (LENVATINIB) CAPSULES FOR FIRST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
07/31/2018
EISAI SIGNS COLLABORATION AGREEMENT FOR ANTI-OBESITY AGENT LORCASERIN IN CHINA TO CY BIOTECH
07/31/2018
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA® in Combination with KEYTRUDA®
07/26/2018
EISAI AND BIOGEN ANNOUNCE DETAILED RESULTS OF PHASE II CLINICAL STUDY OF BAN2401 IN EARLY ALZHEIMER’S DISEASE AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018
07/26/2018
EISAI AND BIOGEN PRESENT DETAILED RESULTS FROM PHASE II CLINICAL STUDY OF ELENBECESTAT IN MCI AND MILD TO MODERATE ALZHEIMER’S DISEASE AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018